- Impact
- 1,682
Two years ago I registered the following domains:
Endolysin.com
Endolysins.com
For those who are not familiar with the term a simple explanation is that an endolysin is produced by phages to punch holes in the cell walls of various types of bacteria (an action called 'lysis'). This is presently being developed to treat various skin infections, including MRSA infections. It is thought that this will replace the use of many antibiotics (especially important as bacterial antibiotic resistance is on the rise).
Staphefekt (TM), an endolysin skin treatment, is the first endolysin treatment allowed to be registered for human use, it is used to treat S. aureus infections.
Other research currently underway is into the use of endolysins being used to fight internal body bacterial infections.
In many ways endolysins offer our best hope of replacing many antibiotics in the near future (3-10 years IMO for widespread growth of usage). Initially I simply thought of these registrations as being akin to registering antibiotic.com and antibiotics.com if I had been able to. But I think that the use of endolysins will become widely used also in other technologies including the food and fermentation technologies, as well as use in manufacturing, mining, and other industrial production technologies.
Holding each domain for 10 years will only cost about £100 ($125), and therefore they will well and truly stay in my pension fund portfolio.
So my question is: Are there any other members here who target medical or medtech current research domain names for long term investment?
Endolysin.com
Endolysins.com
For those who are not familiar with the term a simple explanation is that an endolysin is produced by phages to punch holes in the cell walls of various types of bacteria (an action called 'lysis'). This is presently being developed to treat various skin infections, including MRSA infections. It is thought that this will replace the use of many antibiotics (especially important as bacterial antibiotic resistance is on the rise).
Staphefekt (TM), an endolysin skin treatment, is the first endolysin treatment allowed to be registered for human use, it is used to treat S. aureus infections.
Other research currently underway is into the use of endolysins being used to fight internal body bacterial infections.
In many ways endolysins offer our best hope of replacing many antibiotics in the near future (3-10 years IMO for widespread growth of usage). Initially I simply thought of these registrations as being akin to registering antibiotic.com and antibiotics.com if I had been able to. But I think that the use of endolysins will become widely used also in other technologies including the food and fermentation technologies, as well as use in manufacturing, mining, and other industrial production technologies.
Holding each domain for 10 years will only cost about £100 ($125), and therefore they will well and truly stay in my pension fund portfolio.
So my question is: Are there any other members here who target medical or medtech current research domain names for long term investment?
